VIDEO: KEYNOTE-966 study bodes well for future bile tract cancer studies
Click Here to Manage Email Alerts
In this video, Ahmed Kaseb, MD, CMQ, discussed results from the phase 3 KEYNOTE-966 study, presented at American Association for Cancer Research Annual Meeting.
Kaseb, a professor in the department of gastrointestinal medical oncology at The University of Texas MD Anderson Cancer Center, highlighted the study, which tested a combination therapy of pembrolizumab and gemcitabine/cisplatin in patients with biliary tract cancer, and showed statistically significant progression-free survival.
“Even though the survival benefit is modest, this will work for us as a validation of the benefit of immunotherapy in bile duct cancers, and we’ll see more buildup of that in future studies,” Kaseb said.
Collapse
Read more about
Click Here to Manage Email Alerts